These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28185577)

  • 41. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
    Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
    Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.
    Flahaut M; Jauquier N; Chevalier N; Nardou K; Balmas Bourloud K; Joseph JM; Barras D; Widmann C; Gross N; Renella R; Mühlethaler-Mottet A
    BMC Cancer; 2016 Oct; 16(1):781. PubMed ID: 27724856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation.
    Wang C; Tan J; Jin Y; Li Z; Yang J; Jia Y; Xia Y; Gong B; Dong Q; Zhao Q
    Front Immunol; 2024; 15():1415736. PubMed ID: 38962012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
    Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
    J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
    Chang HH; Lee H; Hu MK; Tsao PN; Juan HF; Huang MC; Shih YY; Wang BJ; Jeng YM; Chang CL; Huang SF; Tsay YG; Hsieh FJ; Lin KH; Hsu WM; Liao YF
    Clin Cancer Res; 2010 Sep; 16(17):4411-20. PubMed ID: 20736329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
    Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
    Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
    Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
    Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells.
    Holmquist L; Jögi A; Påhlman S
    Int J Cancer; 2005 Aug; 116(2):218-25. PubMed ID: 15800931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma.
    Mergui X; Puiffe ML; Valteau-Couanet D; Lipinski M; Bénard J; Amor-Guéret M
    BMC Cancer; 2010 Sep; 10():473. PubMed ID: 20813048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
    Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
    Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.
    Holmquist-Mengelbier L; Fredlund E; Löfstedt T; Noguera R; Navarro S; Nilsson H; Pietras A; Vallon-Christersson J; Borg A; Gradin K; Poellinger L; Påhlman S
    Cancer Cell; 2006 Nov; 10(5):413-23. PubMed ID: 17097563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxia-induced dedifferentiation in neuroblastoma cells.
    Jögi A; Øra I; Nilsson H; Poellinger L; Axelson H; Påhlman S
    Cancer Lett; 2003 Jul; 197(1-2):145-50. PubMed ID: 12880974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells.
    Poomthavorn P; Wong SH; Higgins S; Werther GA; Russo VC
    Endocr Relat Cancer; 2009 Sep; 16(3):991-1004. PubMed ID: 19423615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MDA5 complements TLR3 in suppression of neuroblastoma.
    Hsu WM; Huang CC; Lee HY; Wu PY; Wu MT; Chuang HC; Lin LL; Chuang JH
    Oncotarget; 2015 Sep; 6(28):24935-46. PubMed ID: 26208481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma.
    Roberts SS; Mori M; Pattee P; Lapidus J; Mathews R; O'Malley JP; Hsieh YC; Turner MA; Wang Z; Tian Q; Rodland MJ; Reynolds CP; Seeger RC; Nagalla SR
    J Clin Oncol; 2004 Oct; 22(20):4127-34. PubMed ID: 15483022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage.
    Hoehner JC; Gestblom C; Hedborg F; Sandstedt B; Olsen L; Påhlman S
    Lab Invest; 1996 Nov; 75(5):659-75. PubMed ID: 8941212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.
    Yerukala Sathipati S; Sahu D; Huang HC; Lin Y; Ho SY
    Sci Rep; 2019 Mar; 9(1):5125. PubMed ID: 30914706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.
    Yu Y; Zeng Y; Xia X; Zhou JG; Cao F
    Cancer Control; 2021; 28():10732748211033751. PubMed ID: 34569303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of DDX39A as a Potential Biomarker for Unfavorable Neuroblastoma Using a Proteomic Approach.
    Otake K; Uchida K; Ide S; Kobayashi Y; Kobayashi I; Kusunoki M
    Pediatr Blood Cancer; 2016 Feb; 63(2):221-7. PubMed ID: 26469522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.